AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.51+6.11 (+5.59%) ▲|ACN264.27+9.71 (+3.81%) ▲|ADBE248.48+2.34 (+0.95%) ▲|AMAT369.40-12.52 (-3.28%) ▼|AMD488.78+4.88 (+1.01%) ▲|AMGN478.48+17.22 (+3.73%) ▲|AMT194.86+7.57 (+4.04%) ▲|AMZN266.03+15.34 (+6.12%) ▲|AVGO325.48-6.65 (-2.00%) ▼|AXP332.59+7.09 (+2.18%) ▲|BA177.00+3.69 (+2.13%) ▲|BAC51.63+1.97 (+3.97%) ▲|BKNG170.97+15.30 (+9.83%) ▲|BLK1,224.37+63.05 (+5.43%) ▲|BMY64.19+2.48 (+4.02%) ▲|BNY152.72+3.41 (+2.28%) ▲|BRK-B579.09+22.02 (+3.95%) ▲|C124.74+2.03 (+1.65%) ▲|CAT591.30-32.64 (-5.23%) ▼|CL98.76+3.14 (+3.28%) ▲|CMCSA24.85+1.18 (+4.99%) ▲|COF206.31-2.40 (-1.15%) ▼|COP136.94-7.46 (-5.17%) ▼|COST1,046.47+27.21 (+2.67%) ▲|CRM227.11+4.91 (+2.21%) ▲|CSCO103.61+0.64 (+0.62%) ▲|CVS79.96-11.45 (-12.53%) ▼|CVX216.96-8.31 (-3.69%) ▼|DE676.50+10.67 (+1.60%) ▲|DHR234.93+4.82 (+2.09%) ▲|DIS118.95+4.77 (+4.18%) ▲|DUK129.59+3.08 (+2.43%) ▲|EMR170.44+4.05 (+2.43%) ▲|FDX329.40+11.38 (+3.58%) ▲|GD364.87-9.63 (-2.57%) ▼|GE329.45+8.78 (+2.74%) ▲|GEV832.83-85.37 (-9.30%) ▼|GILD174.48+7.01 (+4.19%) ▲|GM92.43+4.09 (+4.63%) ▲|GOOG287.30+9.03 (+3.25%) ▲|GOOGL288.93+8.90 (+3.18%) ▲|GS928.00+31.91 (+3.56%) ▲|HD355.44+21.78 (+6.53%) ▲|HON228.47+4.42 (+1.97%) ▲|IBM254.32+4.28 (+1.71%) ▲|INTC58.27-2.28 (-3.77%) ▼|INTU356.64+11.92 (+3.46%) ▲|ISRG482.10+41.35 (+9.38%) ▲|JNJ276.32+10.15 (+3.81%) ▲|JPM352.11+14.13 (+4.18%) ▲|KO95.80+1.00 (+1.05%) ▲|LIN524.74+13.19 (+2.58%) ▲|LLY1,417.99+8.61 (+0.61%) ▲|LMT595.04-43.96 (-6.88%) ▼|LOW229.38+16.00 (+7.50%) ▲|LRCX221.43-9.29 (-4.03%) ▼|MA672.68+25.50 (+3.94%) ▲|MCD280.22+17.18 (+6.53%) ▲|MDLZ67.38+2.26 (+3.47%) ▲|MDT104.96+6.08 (+6.15%) ▲|META630.00+8.97 (+1.44%) ▲|MMM193.95+16.90 (+9.55%) ▲|MO78.01+1.07 (+1.39%) ▲|MRK150.36+5.69 (+3.93%) ▲|MS193.97+7.88 (+4.23%) ▲|MSFT555.80+34.81 (+6.68%) ▲|MU795.23-59.87 (-7.00%) ▼|NEE88.45+4.12 (+4.89%) ▲|NFLX66.39+2.97 (+4.68%) ▲|NKE40.49+2.01 (+5.22%) ▲|NOW108.81-0.35 (-0.32%) ▼|NVDA200.13-6.56 (-3.17%) ▼|ORCL123.73-2.46 (-1.95%) ▼|PEP142.42+5.15 (+3.75%) ▲|PFE30.79+0.79 (+2.63%) ▲|PG167.32+5.26 (+3.25%) ▲|PLTR171.70-3.70 (-2.11%) ▼|PM211.28+3.25 (+1.56%) ▲|QCOM173.19+8.76 (+5.33%) ▲|RTX198.43-5.39 (-2.64%) ▼|SBUX109.70+4.93 (+4.71%) ▲|SCHW93.37+4.09 (+4.58%) ▲|SO93.12-0.63 (-0.67%) ▼|SPG228.50+6.42 (+2.89%) ▲|T21.83+0.44 (+2.06%) ▲|TMO706.16+7.82 (+1.12%) ▲|TMUS159.17+4.76 (+3.08%) ▲|TSLA385.19-13.31 (-3.34%) ▼|TXN311.49-1.00 (-0.32%) ▼|UBER69.87+3.27 (+4.91%) ▲|UNH409.38+4.94 (+1.22%) ▲|UNP308.53+5.10 (+1.68%) ▲|UPS114.31+5.14 (+4.71%) ▲|USB61.03+1.14 (+1.90%) ▲|V436.57+16.15 (+3.84%) ▲|VZ46.17+0.93 (+2.06%) ▲|WFC87.43+1.90 (+2.22%) ▲|WMT129.17+4.31 (+3.45%) ▲|XOM169.27-8.19 (-4.62%) ▼|AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.51+6.11 (+5.59%) ▲|ACN264.27+9.71 (+3.81%) ▲|ADBE248.48+2.34 (+0.95%) ▲|AMAT369.40-12.52 (-3.28%) ▼|AMD488.78+4.88 (+1.01%) ▲|AMGN478.48+17.22 (+3.73%) ▲|AMT194.86+7.57 (+4.04%) ▲|AMZN266.03+15.34 (+6.12%) ▲|AVGO325.48-6.65 (-2.00%) ▼|AXP332.59+7.09 (+2.18%) ▲|BA177.00+3.69 (+2.13%) ▲|BAC51.63+1.97 (+3.97%) ▲|BKNG170.97+15.30 (+9.83%) ▲|BLK1,224.37+63.05 (+5.43%) ▲|BMY64.19+2.48 (+4.02%) ▲|BNY152.72+3.41 (+2.28%) ▲|BRK-B579.09+22.02 (+3.95%) ▲|C124.74+2.03 (+1.65%) ▲|CAT591.30-32.64 (-5.23%) ▼|CL98.76+3.14 (+3.28%) ▲|CMCSA24.85+1.18 (+4.99%) ▲|COF206.31-2.40 (-1.15%) ▼|COP136.94-7.46 (-5.17%) ▼|COST1,046.47+27.21 (+2.67%) ▲|CRM227.11+4.91 (+2.21%) ▲|CSCO103.61+0.64 (+0.62%) ▲|CVS79.96-11.45 (-12.53%) ▼|CVX216.96-8.31 (-3.69%) ▼|DE676.50+10.67 (+1.60%) ▲|DHR234.93+4.82 (+2.09%) ▲|DIS118.95+4.77 (+4.18%) ▲|DUK129.59+3.08 (+2.43%) ▲|EMR170.44+4.05 (+2.43%) ▲|FDX329.40+11.38 (+3.58%) ▲|GD364.87-9.63 (-2.57%) ▼|GE329.45+8.78 (+2.74%) ▲|GEV832.83-85.37 (-9.30%) ▼|GILD174.48+7.01 (+4.19%) ▲|GM92.43+4.09 (+4.63%) ▲|GOOG287.30+9.03 (+3.25%) ▲|GOOGL288.93+8.90 (+3.18%) ▲|GS928.00+31.91 (+3.56%) ▲|HD355.44+21.78 (+6.53%) ▲|HON228.47+4.42 (+1.97%) ▲|IBM254.32+4.28 (+1.71%) ▲|INTC58.27-2.28 (-3.77%) ▼|INTU356.64+11.92 (+3.46%) ▲|ISRG482.10+41.35 (+9.38%) ▲|JNJ276.32+10.15 (+3.81%) ▲|JPM352.11+14.13 (+4.18%) ▲|KO95.80+1.00 (+1.05%) ▲|LIN524.74+13.19 (+2.58%) ▲|LLY1,417.99+8.61 (+0.61%) ▲|LMT595.04-43.96 (-6.88%) ▼|LOW229.38+16.00 (+7.50%) ▲|LRCX221.43-9.29 (-4.03%) ▼|MA672.68+25.50 (+3.94%) ▲|MCD280.22+17.18 (+6.53%) ▲|MDLZ67.38+2.26 (+3.47%) ▲|MDT104.96+6.08 (+6.15%) ▲|META630.00+8.97 (+1.44%) ▲|MMM193.95+16.90 (+9.55%) ▲|MO78.01+1.07 (+1.39%) ▲|MRK150.36+5.69 (+3.93%) ▲|MS193.97+7.88 (+4.23%) ▲|MSFT555.80+34.81 (+6.68%) ▲|MU795.23-59.87 (-7.00%) ▼|NEE88.45+4.12 (+4.89%) ▲|NFLX66.39+2.97 (+4.68%) ▲|NKE40.49+2.01 (+5.22%) ▲|NOW108.81-0.35 (-0.32%) ▼|NVDA200.13-6.56 (-3.17%) ▼|ORCL123.73-2.46 (-1.95%) ▼|PEP142.42+5.15 (+3.75%) ▲|PFE30.79+0.79 (+2.63%) ▲|PG167.32+5.26 (+3.25%) ▲|PLTR171.70-3.70 (-2.11%) ▼|PM211.28+3.25 (+1.56%) ▲|QCOM173.19+8.76 (+5.33%) ▲|RTX198.43-5.39 (-2.64%) ▼|SBUX109.70+4.93 (+4.71%) ▲|SCHW93.37+4.09 (+4.58%) ▲|SO93.12-0.63 (-0.67%) ▼|SPG228.50+6.42 (+2.89%) ▲|T21.83+0.44 (+2.06%) ▲|TMO706.16+7.82 (+1.12%) ▲|TMUS159.17+4.76 (+3.08%) ▲|TSLA385.19-13.31 (-3.34%) ▼|TXN311.49-1.00 (-0.32%) ▼|UBER69.87+3.27 (+4.91%) ▲|UNH409.38+4.94 (+1.22%) ▲|UNP308.53+5.10 (+1.68%) ▲|UPS114.31+5.14 (+4.71%) ▲|USB61.03+1.14 (+1.90%) ▲|V436.57+16.15 (+3.84%) ▲|VZ46.17+0.93 (+2.06%) ▲|WFC87.43+1.90 (+2.22%) ▲|WMT129.17+4.31 (+3.45%) ▲|XOM169.27-8.19 (-4.62%) ▼|
18.4 C
New York
Thursday, November 5, 2026

Tag: programs

newsFORsourcecompanycontentinformationreleases1market

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Changsha uses engineering expertise to engage in BRI

BEIJING, June 21, 2025 /PRNewswire/ -- A report from China Daily Engineering machinery is a specialty of Changsha in Central China's Hunan province and a...

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science 
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science

New Research on Abbott’s Healthy Food Rx Program Shows ‘Food is Medicine’ Approach Helps People Living With Diabetes Eat Better and Feel Healthier

Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

The Inner Circle acknowledges, Dr. Ashley Poklar a Pinnacle Professional Member

CHAGRIN, Ohio, June 20, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Ashley Poklar is acknowledged as a Pinnacle Professional Member Inner Circle...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrograms

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers